Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of “Hold” by Analysts

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has been given an average rating of “Hold” by the thirteen research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $16.30.

A number of brokerages have recently issued reports on AARD. Morgan Stanley reaffirmed an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a report on Monday, July 20th. B. Riley Financial reduced their price target on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd.

Aardvark Therapeutics Stock Performance

Shares of Aardvark Therapeutics stock opened at $7.90 on Tuesday. Aardvark Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.94. The stock has a market capitalization of $172.85 million, a price-to-earnings ratio of -2.46 and a beta of 3.81. The company has a fifty day moving average of $5.35 and a 200-day moving average of $6.78.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. On average, equities research analysts forecast that Aardvark Therapeutics will post -3.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Aardvark Therapeutics during the 2nd quarter valued at $42,000. China Universal Asset Management Co. Ltd. bought a new stake in Aardvark Therapeutics in the 4th quarter worth $47,000. Persistent Asset Partners Ltd bought a new stake in Aardvark Therapeutics in the 4th quarter worth $56,000. New York State Common Retirement Fund purchased a new position in shares of Aardvark Therapeutics in the second quarter valued at about $99,000. Finally, MetLife Investment Management LLC purchased a new position in shares of Aardvark Therapeutics in the fourth quarter valued at about $102,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.